Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit due to alleged violations of the Securities Act of 1933 related to its IPO, which took place on September 26, 2024, where it sold 12.65 million shares at $18.00 each [1][2][3]. Group 1: Lawsuit Details - The class action lawsuit, titled Soto v. BioAge Labs, Inc., claims that the IPO offering documents were materially false and misleading, asserting that there were no safety concerns and that the company expected positive results from its STRIDES clinical trial [3][4]. - Following the announcement on December 6, 2024, regarding the discontinuation of the STRIDES Phase 2 study due to liver transaminitis observed in subjects, BioAge Labs' stock price plummeted over 76%, dropping to around $5.82 per share, significantly below the IPO price [4]. Group 2: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased BioAge Labs stock in connection with the IPO to seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. - The lead plaintiff has the authority to select a law firm for litigation and does not need to serve as lead plaintiff to share in any potential recovery [5]. Group 3: Company Background - BioAge Labs is a clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for metabolic diseases [2].
BIOA INVESTOR DEADLINE: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit